The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Molecular Influenza Diagnostic Market Research Report 2025
Synopsis
Molecular assays are a new type of molecular influenza diagnostic test to detect influenza viral RNA or nucleic acids in upper respiratory tract specimens in approximately 15-30 minutes.
The global Molecular Influenza Diagnostic market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Molecular Influenza Diagnostic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Molecular Influenza Diagnostic.
Report Scope
The Molecular Influenza Diagnostic market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Molecular Influenza Diagnostic market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Molecular Influenza Diagnostic companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
BD
Abbott (Include Alere)
Roche
SIEMENS
Analytik Jena
Quidel
Thermo Fisher
Meridian Bioscience
BioMerieux
Sekisui Diagnostics
Response Biomedical
SA Scientific
Segment by Type
Reverse Transcription Polymerase Chain Reaction (RT-PCR)
Nucleic Acid Sequence Based Amplification (NASBA) Tests
Loop-mediated Isothermal Amplification-Based Assays (LAMP)
Simple Amplification-based Assays (SAMBA)
Segment by Application
Hospitals
POCT
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Molecular Influenza Diagnostic companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Molecular assays are a new type of molecular influenza diagnostic test to detect influenza viral RNA or nucleic acids in upper respiratory tract specimens in approximately 15-30 minutes.
The global Molecular Influenza Diagnostic market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Molecular Influenza Diagnostic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Molecular Influenza Diagnostic.
Report Scope
The Molecular Influenza Diagnostic market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Molecular Influenza Diagnostic market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Molecular Influenza Diagnostic companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
BD
Abbott (Include Alere)
Roche
SIEMENS
Analytik Jena
Quidel
Thermo Fisher
Meridian Bioscience
BioMerieux
Sekisui Diagnostics
Response Biomedical
SA Scientific
Segment by Type
Reverse Transcription Polymerase Chain Reaction (RT-PCR)
Nucleic Acid Sequence Based Amplification (NASBA) Tests
Loop-mediated Isothermal Amplification-Based Assays (LAMP)
Simple Amplification-based Assays (SAMBA)
Segment by Application
Hospitals
POCT
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Molecular Influenza Diagnostic companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Molecular Influenza Diagnostic Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Reverse Transcription Polymerase Chain Reaction (RT-PCR)
1.2.3 Nucleic Acid Sequence Based Amplification (NASBA) Tests
1.2.4 Loop-mediated Isothermal Amplification-Based Assays (LAMP)
1.2.5 Simple Amplification-based Assays (SAMBA)
1.3 Market by Application
1.3.1 Global Molecular Influenza Diagnostic Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 POCT
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Molecular Influenza Diagnostic Market Perspective (2019-2030)
2.2 Molecular Influenza Diagnostic Growth Trends by Region
2.2.1 Global Molecular Influenza Diagnostic Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Molecular Influenza Diagnostic Historic Market Size by Region (2019-2024)
2.2.3 Molecular Influenza Diagnostic Forecasted Market Size by Region (2025-2030)
2.3 Molecular Influenza Diagnostic Market Dynamics
2.3.1 Molecular Influenza Diagnostic Industry Trends
2.3.2 Molecular Influenza Diagnostic Market Drivers
2.3.3 Molecular Influenza Diagnostic Market Challenges
2.3.4 Molecular Influenza Diagnostic Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Molecular Influenza Diagnostic Players by Revenue
3.1.1 Global Top Molecular Influenza Diagnostic Players by Revenue (2019-2024)
3.1.2 Global Molecular Influenza Diagnostic Revenue Market Share by Players (2019-2024)
3.2 Global Molecular Influenza Diagnostic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Molecular Influenza Diagnostic Revenue
3.4 Global Molecular Influenza Diagnostic Market Concentration Ratio
3.4.1 Global Molecular Influenza Diagnostic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Molecular Influenza Diagnostic Revenue in 2023
3.5 Molecular Influenza Diagnostic Key Players Head office and Area Served
3.6 Key Players Molecular Influenza Diagnostic Product Solution and Service
3.7 Date of Enter into Molecular Influenza Diagnostic Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Molecular Influenza Diagnostic Breakdown Data by Type
4.1 Global Molecular Influenza Diagnostic Historic Market Size by Type (2019-2024)
4.2 Global Molecular Influenza Diagnostic Forecasted Market Size by Type (2025-2030)
5 Molecular Influenza Diagnostic Breakdown Data by Application
5.1 Global Molecular Influenza Diagnostic Historic Market Size by Application (2019-2024)
5.2 Global Molecular Influenza Diagnostic Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Molecular Influenza Diagnostic Market Size (2019-2030)
6.2 North America Molecular Influenza Diagnostic Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Molecular Influenza Diagnostic Market Size by Country (2019-2024)
6.4 North America Molecular Influenza Diagnostic Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Molecular Influenza Diagnostic Market Size (2019-2030)
7.2 Europe Molecular Influenza Diagnostic Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Molecular Influenza Diagnostic Market Size by Country (2019-2024)
7.4 Europe Molecular Influenza Diagnostic Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Molecular Influenza Diagnostic Market Size (2019-2030)
8.2 Asia-Pacific Molecular Influenza Diagnostic Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Molecular Influenza Diagnostic Market Size by Region (2019-2024)
8.4 Asia-Pacific Molecular Influenza Diagnostic Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Molecular Influenza Diagnostic Market Size (2019-2030)
9.2 Latin America Molecular Influenza Diagnostic Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Molecular Influenza Diagnostic Market Size by Country (2019-2024)
9.4 Latin America Molecular Influenza Diagnostic Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Molecular Influenza Diagnostic Market Size (2019-2030)
10.2 Middle East & Africa Molecular Influenza Diagnostic Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Molecular Influenza Diagnostic Market Size by Country (2019-2024)
10.4 Middle East & Africa Molecular Influenza Diagnostic Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 BD
11.1.1 BD Company Detail
11.1.2 BD Business Overview
11.1.3 BD Molecular Influenza Diagnostic Introduction
11.1.4 BD Revenue in Molecular Influenza Diagnostic Business (2019-2024)
11.1.5 BD Recent Development
11.2 Abbott (Include Alere)
11.2.1 Abbott (Include Alere) Company Detail
11.2.2 Abbott (Include Alere) Business Overview
11.2.3 Abbott (Include Alere) Molecular Influenza Diagnostic Introduction
11.2.4 Abbott (Include Alere) Revenue in Molecular Influenza Diagnostic Business (2019-2024)
11.2.5 Abbott (Include Alere) Recent Development
11.3 Roche
11.3.1 Roche Company Detail
11.3.2 Roche Business Overview
11.3.3 Roche Molecular Influenza Diagnostic Introduction
11.3.4 Roche Revenue in Molecular Influenza Diagnostic Business (2019-2024)
11.3.5 Roche Recent Development
11.4 SIEMENS
11.4.1 SIEMENS Company Detail
11.4.2 SIEMENS Business Overview
11.4.3 SIEMENS Molecular Influenza Diagnostic Introduction
11.4.4 SIEMENS Revenue in Molecular Influenza Diagnostic Business (2019-2024)
11.4.5 SIEMENS Recent Development
11.5 Analytik Jena
11.5.1 Analytik Jena Company Detail
11.5.2 Analytik Jena Business Overview
11.5.3 Analytik Jena Molecular Influenza Diagnostic Introduction
11.5.4 Analytik Jena Revenue in Molecular Influenza Diagnostic Business (2019-2024)
11.5.5 Analytik Jena Recent Development
11.6 Quidel
11.6.1 Quidel Company Detail
11.6.2 Quidel Business Overview
11.6.3 Quidel Molecular Influenza Diagnostic Introduction
11.6.4 Quidel Revenue in Molecular Influenza Diagnostic Business (2019-2024)
11.6.5 Quidel Recent Development
11.7 Thermo Fisher
11.7.1 Thermo Fisher Company Detail
11.7.2 Thermo Fisher Business Overview
11.7.3 Thermo Fisher Molecular Influenza Diagnostic Introduction
11.7.4 Thermo Fisher Revenue in Molecular Influenza Diagnostic Business (2019-2024)
11.7.5 Thermo Fisher Recent Development
11.8 Meridian Bioscience
11.8.1 Meridian Bioscience Company Detail
11.8.2 Meridian Bioscience Business Overview
11.8.3 Meridian Bioscience Molecular Influenza Diagnostic Introduction
11.8.4 Meridian Bioscience Revenue in Molecular Influenza Diagnostic Business (2019-2024)
11.8.5 Meridian Bioscience Recent Development
11.9 BioMerieux
11.9.1 BioMerieux Company Detail
11.9.2 BioMerieux Business Overview
11.9.3 BioMerieux Molecular Influenza Diagnostic Introduction
11.9.4 BioMerieux Revenue in Molecular Influenza Diagnostic Business (2019-2024)
11.9.5 BioMerieux Recent Development
11.10 Sekisui Diagnostics
11.10.1 Sekisui Diagnostics Company Detail
11.10.2 Sekisui Diagnostics Business Overview
11.10.3 Sekisui Diagnostics Molecular Influenza Diagnostic Introduction
11.10.4 Sekisui Diagnostics Revenue in Molecular Influenza Diagnostic Business (2019-2024)
11.10.5 Sekisui Diagnostics Recent Development
11.11 Response Biomedical
11.11.1 Response Biomedical Company Detail
11.11.2 Response Biomedical Business Overview
11.11.3 Response Biomedical Molecular Influenza Diagnostic Introduction
11.11.4 Response Biomedical Revenue in Molecular Influenza Diagnostic Business (2019-2024)
11.11.5 Response Biomedical Recent Development
11.12 SA Scientific
11.12.1 SA Scientific Company Detail
11.12.2 SA Scientific Business Overview
11.12.3 SA Scientific Molecular Influenza Diagnostic Introduction
11.12.4 SA Scientific Revenue in Molecular Influenza Diagnostic Business (2019-2024)
11.12.5 SA Scientific Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
